Gilead Keeps Focus On HIV, Long-Acting Drugs And Growth Through Oncology

Ever since CEO Daniel O’Day took the helm and brought in new commercial and research leadership more than three years ago, Gilead Sciences, Inc. has made the case that it would maintain its dominance in HIV while investing to diversify and grow its revenue base by adding high-value cancer drugs to its portfolio. Gilead has encountered skepticism from investors along the way, but the strategy is unchanged, and management insists that is making progress.

Chief commercial officer Johanna Mercier noted in an interview with Scrip during the recent J.P. Morgan Healthcare Conference that “there's a big cultural shift” when an organization the size of Gilead goes through this kind of change, bringing in the science and other support that it needs to expand in a new therapeutic area